LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

5.49 -0.72

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.39

Max

5.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

-8M

Pelno marža

-13,764.773

Darbuotojai

31

EBITDA

-360K

-10M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+122.56% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

74M

406M

Ankstesnė atidarymo kaina

6.21

Ankstesnė uždarymo kaina

5.49

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-27 22:51; UTC

Uždarbis

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Rev $4.01B

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Adj EPS $1.84

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H EPS $1.82

2025-08-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025-08-27 23:39; UTC

Uždarbis

Correction to Nvidia Earnings Article -- WSJ

2025-08-27 22:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-27 22:59; UTC

Rinkos pokalbiai

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025-08-27 22:58; UTC

Uždarbis

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025-08-27 22:57; UTC

Uždarbis

South32 FY Free Cash Flow $192 Million

2025-08-27 22:56; UTC

Uždarbis

South32 FY Total Capital Expenditure $1.35 Billion

2025-08-27 22:56; UTC

Uždarbis

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025-08-27 22:55; UTC

Uždarbis

South32 Net Cash $123 Million at June 30

2025-08-27 22:54; UTC

Uždarbis

South32: Focused on Maintaining Strong Operating Momentum

2025-08-27 22:53; UTC

Uždarbis

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025-08-27 22:53; UTC

Uždarbis

South32 Extends Capital Management Program for 12 Months

2025-08-27 22:52; UTC

Uždarbis

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025-08-27 22:50; UTC

Uždarbis

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025-08-27 22:50; UTC

Uždarbis

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025-08-27 22:45; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025-08-27 22:43; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025-08-27 22:43; UTC

Uždarbis

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources Net Debt $123 Million at June 30

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources FY Underlying Ebitda $527.7 Million

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

122.56% į viršų

12 mėnesių prognozė

Vidutinis 12.33 USD  122.56%

Aukščiausias 15 USD

Žemiausias 11 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.